Key facts
- Amazon's RxPass subscription plan costs $5 per month for Prime members.
- GoodRx's Companion plan costs $14.99 per month and includes discounts on telehealth and other services.
- GoodRx's subscription revenue rose 39% to $28.5 million in the second quarter.
- Amazon's RxPass has seen customer numbers grow nearly threefold since its 2023 launch.
- Millions of Americans are expected to drop individual health insurance plans offered under the Affordable Care Act in 2026.
- Employer-sponsored health insurance costs are projected to rise up to 11% in 2027.
Amazon and GoodRx are experiencing a surge in demand for their flat-fee prescription drug subscription services as consumers seek to mitigate rising healthcare costs and navigate a landscape of dwindling health insurance options. These services, which offer access to select generic drugs for a predictable monthly fee, are proving attractive to Americans facing increasing premiums and out-of-pocket expenses.
Amazon's RxPass, available to Prime members for $5 per month, has seen its customer base grow nearly threefold since its launch in 2023. John Love, vice president at Amazon Pharmacy, noted that over 70% of users fill three or more different medications, indicating the program's utility for individuals with ongoing health needs. Similarly, GoodRx's Companion plan, priced at $14.99 per month, offers discounts on telehealth, vision, dental, and lab services, in addition to select generic drugs. GoodRx reported a 39% increase in subscription revenue to $28.5 million in the second quarter, with subscription plans overall growing 14% in the same period.
Analysts suggest these subscription models can offer significant savings, particularly for individuals managing multiple prescriptions or those enrolled in high-deductible health plans. "If someone is on multiple drugs, this kind of subscription can make a lot of sense," said Jailendra Singh, an analyst at Truist. William Soliman, chief investment officer at White Manna Capital Partners, highlighted the simplicity and predictability of Amazon's $5 monthly price as a key advantage amidst complex coverage changes.
While these plans provide access to a limited number of generic drugs (around 50 for Amazon and over 250 for GoodRx, out of approximately 30,000 approved in the U.S.), they are seen as a complement to traditional insurance. GoodRx CEO Wendy Barnes stated the plan is drawing consumers squeezed by higher deductibles and narrower drug formularies. Other companies, like Mark Cuban's Cost Plus Drugs, offer generics at prices below typical co-pays, based on acquisition cost plus a 15% markup, providing an alternative to subscription models.
Analysts believe these subscription services can also drive customers to other products and services offered by these companies. For instance, Amazon offers One Medical primary care discounts to Prime subscribers. Tom Hulick, managing partner at Strategy Asset Managers, suggested Amazon could become a central hub for healthcare services. While RxPass revenue is expected to be modest compared to Amazon's overall revenue, its value may lie in strengthening Prime subscriptions and directing users to Amazon Pharmacy.